Skip to main content
. 2024 Jul 26;42(31):3680–3691. doi: 10.1200/JCO.23.02363

FIG A3.

FIG A3.

Subgroup analysis of (A) progression-free survival assessed by blinded independent review committee and (B) overall survival in patients with different metastases sites and different mutation sites. METex14, MET exon 14; OS, overall survival; PFS, progression-free survival.